Page 2 - Markl Baum News Today

29.11.2023 - Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Application (NDA) for TRIESENCE (triamcinolone acetonide injectable suspension) 40 mg/mL, a synthetic ... Seite 1

Operator: Good afternoon, and welcome to Harrows Third Quarter 2023 Earnings Conference Call. My name is Betsy, and I will be your operator for todays call.

Adjusted EBITDA Soars by 270% Year-Over-Year Amidst Operational Challenges

Mendota Financial Group LLC lowered its holdings in shares of Harrow Health, Inc. (NASDAQ:HROW – Free Report) by 4.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 19,073 shares of the company’s stock after selling 884 shares during the […]

Westside Investment Management Inc. reduced its stake in Harrow Health, Inc. (NASDAQ:HROW – Free Report) by 11.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 133,744 shares of the company’s stock after selling 16,865 shares during the quarter. Westside Investment […]

Invictus Private Wealth LLC lowered its stake in Harrow Health, Inc. (NASDAQ:HROW – Free Report) by 17.4% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 639,316 shares of the company’s stock after selling 134,806 shares during the period. Harrow Health makes up about 1.6% […]

Harrow Health, Inc. (NASDAQ:HROW – Get Free Report)’s share price was up 6.5% during trading on Monday . The stock traded as high as $15.89 and last traded at $15.80. Approximately 191,766 shares were traded during trading, a decline of 58% from the average daily volume of 455,751 shares. The stock had previously closed at […]

Harrow Health, Inc. (NASDAQ:HROW – Get Free Report) CEO Mark L. Baum acquired 5,800 shares of the company’s stock in a transaction that occurred on Monday, August 14th. The shares were acquired at an average price of $17.05 per share, with a total value of $98,890.00. Following the completion of the transaction, the chief executive […]

Harrow Health, Inc. (NASDAQ:HROW – Get Free Report)’s stock price gapped up before the market opened on Tuesday following insider buying activity. The stock had previously closed at $17.28, but opened at $17.64. Harrow Health shares last traded at $17.73, with a volume of 81,425 shares trading hands. Specifically, CEO Mark L. Baum acquired 5,800 […]

Second Quarter 2023 and Recent Selected Highlights:Record revenues of $33.5 million, an increase of 44% over $23.3 million in the prior-year quarter and an increase of 28% over $26.1 million in the sequential quarter.GAAP net loss of ($4.2) million.Record adjusted EBITDA of $11.0 million, an increase of 144% over $4...